PHAT
NASDAQPhathom Pharmaceuticals Inc.
News · 26 weeks50-82%
2025-12-282026-06-21
Mix2390d
- Insider8(35%)
- SEC Filings7(30%)
- Other5(22%)
- Earnings2(9%)
- Analyst1(4%)
Latest news
25 items- SECSEC Form 8-K filed by Phathom Pharmaceuticals Inc.8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
- PRPhathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoETopline results for the double-blind 12-week treatment portion of the study are expected in Q4 of 2026 FLORHAM PARK, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA® (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis (EoE) in adults. The study has enrolled 95 patients at 41 U.S. sites. Topli
- INSIDERDirector Parikh Asit received a gift of 28,000 shares and gifted 28,000 shares, decreasing direct ownership by 54% to 24,122 units (SEC Form 4)4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
- PRPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesFLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in May and June: Craig-Hallum 23rd Annual Institutional Investor Conference in Minneapolis, MNDate: Thursday, May 28, 2026 Management to participate in one-on-one meetings throughout the conference Jefferies Global Healthcare Conference in New York, NYDate: Wednesday, June 3, 2026Fireside Chat: 12:15 pm EDTManagement to participate in one-on-one
- INSIDERDirector Parikh Asit was granted 24,122 shares and exercised 17,500 shares at a strike of $4.95, increasing direct ownership by 396% to 52,122 units (SEC Form 4)4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
- INSIDERDirector Fields Heidi was granted 24,122 shares, increasing direct ownership by 80% to 54,122 units (SEC Form 4)4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
- INSIDERDirector Topper James N was granted 24,122 shares, increasing direct ownership by 57% to 66,718 units (SEC Form 4)4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
- INSIDERDirector Stenhouse Mark was granted 24,122 shares, increasing direct ownership by 80% to 54,122 units (SEC Form 4)4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
- INSIDERDirector Schroeder Theodore R was granted 24,122 shares, increasing direct ownership by 115% to 45,122 units (SEC Form 4)4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
- INSIDERDirector Cola Michael F was granted 24,122 shares, increasing direct ownership by 61% to 63,920 units (SEC Form 4)4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
- INSIDERDirector Karbe Frank was granted 24,122 shares, increasing direct ownership by 36% to 91,622 units (SEC Form 4)4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
- SECSEC Form 8-K filed by Phathom Pharmaceuticals Inc.8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
- PRPhathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research abstractsIndependent investigator-initiated studies reported findings on treatment of GERD, H. pylori eradication, long-term safety, and vonoprazan use post endoscopic submucosal dissection (ESD)Phathom-sponsored analysis of heartburn and regurgitation in patients on vonoprazan from the Phase 3 pHalcon-NERD-301 trial recognized by DDW as a Poster of Distinction FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commer
- PRPhathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual MeetingFLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the Digestive Disease Week® (DDW) 2026 annual meeting, being held May 2–5 in Chicago, Illinois. Phathom will engage with the medical and scientific community through a series of activities, including a product theater presentation on VOQUEZNA® (vonoprazan), a first-in-class potassium-competitive acid blocker (PCAB) approved for Gastroesophageal Reflux Disease (GERD), on Monday, May 4 at 12:00 PM CDT, along with a presence on the exhibi
- SECSEC Form 10-Q filed by Phathom Pharmaceuticals Inc.10-Q - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
- SECSEC Form 8-K filed by Phathom Pharmaceuticals Inc.8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
- PRPhathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update~1.35 million total VOQUEZNA® prescriptions filled to date$58.3 million in Q1 net revenues, a 104% increase year-over-yearQ1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2 million and net cash usage of ~$15 million, reflecting continued expense discipline and significant year-over-year cost reductionFY 2026 guidance maintained; operating profitability expected beginning in Q3 2026 and for FY 2026Conference call and webcast today, April 30, 2026, at 8:00 a.m. EDT FLORHAM PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointest
- PRPhathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, April 30, 2026, to report its first quarter 2026 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations.
- SECSEC Form DEFA14A filed by Phathom Pharmaceuticals Inc.DEFA14A - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
- SECSEC Form DEF 14A filed by Phathom Pharmaceuticals Inc.DEF 14A - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
- PRPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesFLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in April: Raymond James 2026 Biotech Innovation Symposium in New York, NYDate: Tuesday, April 14, 2026 Management to participate in one-on-one meetings throughout the conference 25th Annual Needham Virtual Healthcare ConferenceDate: Wednesday, April 15, 2026Fireside Chat: 1:30 pm EDTManagement to participate in one-on-one meetings throughout t
- SECSEC Form S-8 filed by Phathom Pharmaceuticals Inc.S-8 - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
- ANALYSTPhathom Pharmaceuticals upgraded by Barclays with a new price targetBarclays upgraded Phathom Pharmaceuticals from Equal Weight to Overweight and set a new price target of $18.00
- SECSEC Form SCHEDULE 13G filed by Phathom Pharmaceuticals Inc.SCHEDULE 13G - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)
- INSIDERSEC Form 4 filed by Phathom Pharmaceuticals Inc.4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
PHAT FAQ
7 questionsWhat does Phathom Pharmaceuticals Inc. do?
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is...Where does PHAT stock trade?
Phathom Pharmaceuticals Inc. (PHAT) is listed on NASDAQ.What sector and industry is PHAT in?
Phathom Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Phathom Pharmaceuticals Inc. go public?
Phathom Pharmaceuticals Inc. (PHAT) completed its IPO in 2019.What are analysts saying about PHAT?
Phathom Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $1800.00 price target on 2026-03-27. Recent price targets range from $1600.00 to $2800.00.What companies are similar to PHAT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PHAT side-by-side with any of them on Quantisnow.How can I track PHAT on Quantisnow?
Quantisnow aggregates Phathom Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PHAT to receive live email and push alerts on every new disclosure.